Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Invivyd Inc IVVD

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through... see more

Current News (NDAQ:IVVD)

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

GlobeNewswire 12 days ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

GlobeNewswire 12 days ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

GlobeNewswire March 2, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 2, 2026

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

GlobeNewswire February 24, 2026

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

GlobeNewswire February 3, 2026

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

GlobeNewswire January 22, 2026

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

GlobeNewswire January 20, 2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

GlobeNewswire January 8, 2026

Opinion & Analysis (NDAQ:IVVD)

No current opinion is available.

Bullboard Posts (NDAQ:IVVD)

Buy buddy buy.

Otherwise FOMO 
coolfooldumbguy - November 17, 2025

GSIW 1$ Breakout Coming Shorts will have to Buy to Cover

GSIW 1$ Breakout Coming Shorts will have to Buy to Cover
10QKing - February 7, 2025

Still staying with this stock and

It's looking really good here for the shareholders today.
coolfooldumbguy - February 7, 2025

Using technical analysis for this stock.

It's looking really good here for this one this morning.
coolfooldumbguy - February 6, 2025

Buy buddy buy because it's taking off this morning.

And furthermore,you guys out there will be missing out.Wow
coolfooldumbguy - February 6, 2025

ADGI APPOINT DAVID HERING AS INTERIM CEO

EOM
Humanist - February 23, 2022

Podcasts